Business · 18/10/2018Updated: 10/17/2026 · 1 min read
FDA Announces Patent Extension Review Period for Food and Drug Administration
Summary
The Food and Drug Administration (FDA) has issued a determination regarding the regulatory review period for purposes of patent extension, as required by the AFSTYLA Act, for the patent in question.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →